Last updated: February 19, 2026
ZAVESCA (generic: rimegepant) is a prescription medication approved for the acute treatment of migraine with or without aura in adults. It belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists. Several suppliers manufacture and distribute ZAVESCA worldwide, primarily through licensing agreements with the patent holders.
Key Suppliers and Manufacturers
1. Pfizer Inc.
- Role: Responsible for the development and commercialization of ZAVESCA (rimegepant) in multiple territories.
- Market Presence: ZAVESCA was approved by the U.S. FDA in 2020 under Pfizer's portfolio.
- Manufacturing: Pfizer produces ZAVESCA through its global network of manufacturing facilities, adhering to high-quality standards.
2. Biohaven Pharmaceuticals
- Role: Original developer of rimegepant before licensing agreements.
- Partnership: Biohaven held rights to develop, market, and distribute ZAVESCA in certain regions.
- Transition: Pfizer acquired Biohaven's global rights to rimegepant in 2022, expanding its distribution capacity.
3. Contract Manufacturing Organizations (CMOs)
- Examples: Catalent, Lonza, and Patheon.
- Function: These firms produce active pharmaceutical ingredients (API) and fill-finish manufacturing for Pfizer and partners.
- Capacity: Capable of large-scale GMP production to meet market demand.
Licensing and Distribution Networks
- Pfizer manages the global supply chain, including distribution through licensed distributors and specialty pharmacies.
- Specific regional licensing agreements may involve local pharmaceutical companies, especially in emerging markets.
Regional Availability
| Region |
Supplier Status |
Notes |
| North America |
Pfizer |
Exclusively licensed distributor; FDA approval in 2020. |
| Europe |
Pfizer |
Approved by EMA in 2021 under Pfizer's branding. |
| Asia-Pacific |
Varies |
Local licensing in countries like Japan and South Korea. |
| Latin America |
Regional partners |
Licensing agreements vary by country. |
Competition and Alternative Sources
- As of 2023, ZAVESCA's primary supplier is Pfizer.
- Alternatives include other CGRP inhibitors, such as ubrogepant (Ubrelvy) and erenumab (Aimovig), produced by different manufacturers.
Supply Chain Considerations
- Production relies on specialized synthesis of rimegepant API.
- Supply chain disruptions may occur due to global logistics or manufacturing issues at CMOs.
- Patent protections and licensing restrict unauthorized manufacturing in most regions.
Summary
Primary supplier: Pfizer Inc. with manufacturing supported by CMOs such as Catalent and Lonza. Distribution channels are governed by licensing agreements in regions worldwide. Pfizer maintains dominance following its acquisition of Biohaven's rights to rimegepant.
Key Takeaways
- Pfizer is the primary supplier, with manufacturing through contracted CMOs.
- ZAVESCA was FDA-approved in 2020 and EMA-approved in 2021.
- Licensing agreements influence regional distribution.
- Alternative CGRP antagonists are available but supplied by different manufacturers.
- Supply chain stability depends on manufacturing capacity and logistics.
FAQs
1. Who manufactures ZAVESCA?
Pfizer Inc. produces ZAVESCA, utilizing contracted CMOs for synthesis and packaging.
2. Are there regional licensing restrictions for ZAVESCA?
Yes. Licensing agreements determine distribution rights, which vary by country and region.
3. Has Pfizer acquired rights to ZAVESCA globally?
Pfizer acquired Biohaven's rights to rimegepant in 2022, expanding global access.
4. Can other companies produce generic versions of ZAVESCA?
Not legally; patent protections limit generic manufacturing outside authorized regions.
5. What are risks to supplier stability?
Manufacturing delays at CMOs, supply chain disruptions, and patent litigation pose risks.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves first medication for acute treatment of migraine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-acute-treatment-migraine
[2] European Medicines Agency. (2021). EMA recommends approval for rimegepant for acute migraine. https://www.ema.europa.eu/en/news/ema-recommends-approval-rimegepant-acute-migraine
[3] Pfizer Inc. Annual Report. (2022). https://www.pfizer.com/investors/annual-report
[4] Biohaven Pharmaceuticals. (2021). Rimegepant patent and licensing details. https://www.biohavenpharma.com/ip
[5] ClinicalTrials.gov. (2020). ZAVESCA (rimegepant) clinical trial data. https://clinicaltrials.gov/ct2/show/NCT04085327
